Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib combinations versus placebo plus carboplatin/paclitaxel in BRCA-mutated metastatic breast cancer
NL-OMON40393Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of veliparib in breast cancer (3 arms), sponsored by AbbVie Inc. Primary endpoint: Progression-free survival. Started Nov 2013; status: active, not recruiting.
02
Drugs
veliparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON40393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40393.